Navigation Links
PDX in Medical News

Emdeon Acquires eRx Network, LLC

...ition, Emdeon, PDX, Inc. and eRx entered into a long term extension and expansion of the strategic relationship that has been in place between eRx and pdx since eRx's founding. "We are delighted to combine our pharmacy business with eRx," said George Lazenby, chief executive officer of Emdeon. "Th...

PDX-Rx.com Works With Microsoft HealthVault to Make Prescription Data Available to Patients

...TM) FORT WORTH, Texas, June 9 /PRNewswire/ -- pdx and Rx.com have entered into a strategic agreement...ients' prescription history into HealthVault. Each pdx pharmacy client will have their own independent relationship with Microsoft, while pdx serves to technically integrate the pharmacy's dat...

Albertson's, LLC Selects PDX-NHIN-Rx.com to Provide Complete Pharmacy Management Solution

...- Boise, Idaho-based Albertson's, LLC has selected pdx and affiliates Rx.com and NHIN as its turnkey part...ess was pharmacy software development. In the end, pdx best met our needs." George Owens, Senior Vice President at pdx said, "We are especially pleased to have Albertson...

New lymphoma therapies targets diverse and difficult cancer

...ne at Columbia University College of Physicians and Surgeons. One of the most promising new therapies developed at NewYork-Presbyterian/Columbia is pdx (pralatrexate) for T-cell lymphoma -- among the most fatal forms of the disease. The drug is uniquely designed to camouflage itself as a folic acid, w...

Allos Therapeutics Appoints Bruce K. Bennett as Vice President, Manufacturing

... agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or SPA process. The Company is also investigating pdx in patients with non-small cell lung cancer and a range of lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeut...

Allos Therapeutics to Present at the 2007 RBC Capital Markets Healthcare Conference

... agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or SPA process. The Company is also investigating pdx in patients with non-small cell lung cancer and a range of lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeut...

PDX-NHIN and Health Market Science to Jointly Market Standardized Prescriber File

...ave entered into an agreement to jointly market to pdx Pharmacy System users the HMS Prescriber Master Fi... provided through NHIN in a manner that will allow pdx customers to access this data using PDX Distributed Processing, a feature of the pdx Pharmacy System that allows access to databases in...

Allos Therapeutics Reports Third Quarter 2007 Financial Results

...September 30, 2007 were $63.4 million. "With five pdx trials ongoing and two additional studies schedule...ke important progress advancing the development of pdx in hematologic malignancies and solid tumors," sta...er of Allos. "PROPEL, our pivotal Phase 2 trial of pdx in patients with relapsed or refractory peripheral...

Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference

... agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or SPA process. The Company is also investigating pdx in patients with non-small cell lung cancer and a range of other lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemothe...

HealthShares(TM) Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...et, Inc. HNT 311854162.6 Davita Inc DVA 230769230.8 Pediatrix Medical Group pdx 173618639.9 Humana Inc. HUM 138944124.3 Healthsouth Corp HLS 525336900.2 Che...
PDX in Medical Technology

Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma

WESTMINSTER, Colo., Dec. 27 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH ) today announced that an independent Data Monitoring Committee (DMC) has completed the pre-specified 65-patient safety review of data from the Company's pivotal Phase 2 PROPEL trial of PDX (pralatrex...

Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma

PROPEL Enrollment Ahead of Schedule with Completion Expected Q2 2008 WESTMINSTER, Colo., Sept. 24 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH ) today announced the completion of pre-planned interim analyses of patient response and safety data from the Company's pivotal ...

Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma

WESTMINSTER, Colo., Aug. 15 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH ) today announced the initiation of patient enrollment in a Phase 1, open-label, multi-center study of the Company's novel antifolate PDX (pralatrexate) with vitamin B12 and folic acid supplementation...

Allos Therapeutics' PDX Granted Orphan Medicinal Product Designation by the European Commission

WESTMINSTER, Colo., April 19, 2007 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. today announced that the Commission of the European Communities, with a favorable opinion of the Committee for Orphan Medicinal Products of the European Medicines Agency (EMEA), has granted orphan drug designatio...

Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma

... agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or SPA process. The Company is also investigating pdx in patients with non-small cell lung cancer and a range of lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeut...

ApoCell's Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy

...t. ApoCell has developed an analytical tool, the pdx Index(TM) (Pharmaco-Diagnostic Index), which indic...President and CEO comments, "We have developed the pdx Index(TM) methodology to give drug developers, cli...e same cancer drug therapy. By knowing a patient's pdx Index(TM) score ahead of time, the physician can p...

Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer

...faproxyn and focus on advancing the development of pdx (pralatrexate), its novel antifolate currently und...rmination in advancing the clinical development of pdx and RH1, and look forward to providing future upda...icer. "We expect to provide the next update on our pdx PROPEL study later this year following completion ...
PDX in Biological News

A molecular switch turns on the flame in 'nature's blowtorch'

...orientation around the peptide bond, and moves the P450 from the form in which substrate binds to the active form. After the reaction is finished, the pdx falls off, the P450 moves back to the unactivated state, and the oxidized products are free to leave. After another substrate molecule and oxygen m...
PDX in Biological Technology

Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference

MTD in NSCLC Identified; Phase 2 Study Planned WESTMINSTER, Colo., Oct. 25 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH ), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, ...

Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference

... agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or SPA process. The Company is also investigating pdx in patients with non-small cell lung cancer and a range of lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeut...

Allos Therapeutics to Present at the 2007 JMP Securities Healthcare Focus Conference

... agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or SPA process. The Company is also investigating pdx in patients with non-small cell lung cancer and a range of other lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemothe...

Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference

...ntly under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investigating pdx in patients with non-small cell lung cancer and a range of other lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemothe...

Allos Therapeutics to Present at the Bear Stearns 20th Annual Healthcare Conference

...ntly under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investigating pdx in patients with non-small cell lung cancer and a range of other lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemothe...
Other Tags
(Date:9/18/2014)... German . ... the ,International Space Station Research Competition, with their project ... scientists will see the International Space Station crew perform ... two proteins of the hepatitis C virus under microgravity ... Space Station is scheduled to lift off from Cape ...
(Date:9/18/2014)... 2014 According to a new market report ... - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, ... was valued at USD 77607.7 million in 2013 and is ... to 2020, to reach an estimated value of USD 115474.9 ... market is growing at a rapid pace due to increasing ...
(Date:9/18/2014)... September 18, 2014 “Awesome” is the ... (Smart Teens Accepting Responsibility Today) Internship Program at ARDX ... Darcy C. describe the program as “Inspirational” and “Life-changing,” ... idea about what they would be doing during their ... do food runs and other mindless tasks,” but, instead ...
(Date:9/18/2014)... HealthDay Reporter WEDNESDAY, ... may be associated with increased odds of developing Parkinson,s ... research suggests. The study, which did not prove ... suggested that the migraine-Parkinson,s association was stronger in women ... warning sign of a pending attack that includes flashes ...
(Date:9/18/2014)... 2014 How much is a serving? ... the factors contributing to the obesity epidemic in the ... serving and how to manage portion size during the ... 3 at Humility House, 755 Ohltown Road, Austintown. , ... the informational discussion and answer questions from 12:30 to ...
Breaking Medicine News(10 mins):Health News:Hepatitis C virus proteins in space 2Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 2Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 3Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 4Health News:ARDX Internship Helps Students to START on the Right Business Path 2Health News:ARDX Internship Helps Students to START on the Right Business Path 3Health News:ARDX Internship Helps Students to START on the Right Business Path 4Health News:Are Migraines in Middle Age Tied to Raised Parkinson's Risk Later? 2Health News:Are Migraines in Middle Age Tied to Raised Parkinson's Risk Later? 3Health News:HMHP Workshop Addresses Portion Control 2
(Date:9/17/2014)... SAN DIEGO, Calif. (Sept. 17, 2014) A rare genetic ... autism, according to a recent joint investigation by researchers ... California, San Diego. In addition to suggesting better treatment ... offers more clues into the genetic underpinnings of autism., ... to the National Institutes of Health. It occurs in ...
(Date:9/17/2014)... at IMIM (Hospital del Mar Medical Research Institute) and ... published a study in eLife showing that ... the evolution of new proteins, some of which could ... produce proteins from the instructions found in an RNA ... RNA containing information for the synthesis of proteins, meaning ...
(Date:9/17/2014)... DALLAS September 17, 2014 Researchers at UTSouthwestern ... of the circulating protein apolipoprotein E, called apoE3, helps ... variant, called apoE4, do not get the benefit of ... disease. , "We believe that we have identified one ... and why a genetic variant, apoE4, is detrimental," said ...
Breaking Biology News(10 mins):A link between Jacobsen syndrome and autism 2Parts of genome without a known function may play a key role in the birth of new proteins 2Protein variant may boost cardiovascular risk by hindering blood vessel repair 2
Other Contents